BP-897

BP-897
Clinical data
ATC code	none;
Identifiers
	IUPAC name N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide;
CAS Number	314776-92-6 ;
PubChem CID	3038495;
IUPHAR/BPS	7625;
ChemSpider	2302059 ;
UNII	20PLE5W821;
ChEMBL	ChEMBL25236 ;
CompTox Dashboard (EPA)	DTXSID60953482 ;
ECHA InfoCard	100.150.041
Chemical and physical data
Formula	C26H31N3O2
Molar mass	417.553 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccccc1N3CCN(CC3)CCCCNC(=O)c4ccc2ccccc2c4;
	InChI InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30) ; Key:MNHDKMDLOJSCGN-UHFFFAOYSA-N ;
	(what is this?) (verify)

BP-897 is a drug used in scientific research which acts as a potent selective dopamine D₃ receptor partial agonist with an in vitro intrinsic activity of ~0.6 and ~70x greater affinity for D₃ over D₂ receptors and is suspected to have partial agonist or antagonist activity in vivo.^[1] It has mainly been used in the study of treatments for cocaine addiction.^[2]^[3]^[4]^[5]^[6]^[7]^[8] A study comparing BP-897 with the potent, antagonistic, and highly D₃ selective SB-277,011-A found, "SB 277011-A (1–10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."^[9]

References[edit]

^ Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, et al. (July 1999). "Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist". Nature. 400 (6742): 371–375. doi:10.1038/22560. PMID 10432116. S2CID 4351316.
^ Beardsley PM, Sokoloff P, Balster RL, Schwartz JC (February 2001). "The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered". Behavioural Pharmacology. 12 (1): 1–11. doi:10.1097/00008877-200102000-00001. PMID 11270507. S2CID 25443354.
^ Garcia-Ladona FJ, Cox BF (2003). "BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction". CNS Drug Reviews. 9 (2): 141–158. doi:10.1111/j.1527-3458.2003.tb00246.x. PMC 6741652. PMID 12847556.
^ Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiébot MH (November 2003). "Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats". Neuropsychopharmacology. 28 (11): 1903–1915. doi:10.1038/sj.npp.1300276. PMID 12915863.
^ Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M (November 2004). "Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics. 311 (2): 770–777. doi:10.1124/jpet.104.071142. PMID 15226382. S2CID 15481124.
^ Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, et al. (July 2005). "Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors". Synapse. 57 (1): 17–28. doi:10.1002/syn.20152. PMC 3726034. PMID 15858839.
^ Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, et al. (March 2008). "The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats". Psychopharmacology. 196 (4): 533–542. doi:10.1007/s00213-007-0986-6. PMC 3713235. PMID 17985117.
^ Hocke C, Prante O, Salama I, Hübner H, Löber S, Kuwert T, Gmeiner P (May 2008). "18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor". ChemMedChem. 3 (5): 788–793. doi:10.1002/cmdc.200700327. PMID 18306190. S2CID 23143152.
^ Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, et al. (March 2010). "The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking". The International Journal of Neuropsychopharmacology. 13 (2): 181–190. doi:10.1017/S1461145709991064. PMID 19995481.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid10432116-1] Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, et al. (July 1999). "Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist". Nature. 400 (6742): 371–375. doi:10.1038/22560. PMID 10432116. S2CID 4351316.

[pmid11270507-2] Beardsley PM, Sokoloff P, Balster RL, Schwartz JC (February 2001). "The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered". Behavioural Pharmacology. 12 (1): 1–11. doi:10.1097/00008877-200102000-00001. PMID 11270507. S2CID 25443354.

[pmid12847556-3] Garcia-Ladona FJ, Cox BF (2003). "BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction". CNS Drug Reviews. 9 (2): 141–158. doi:10.1111/j.1527-3458.2003.tb00246.x. PMC 6741652. PMID 12847556.

[pmid12915863-4] Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiébot MH (November 2003). "Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats". Neuropsychopharmacology. 28 (11): 1903–1915. doi:10.1038/sj.npp.1300276. PMID 12915863.

[pmid15226382-5] Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M (November 2004). "Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics. 311 (2): 770–777. doi:10.1124/jpet.104.071142. PMID 15226382. S2CID 15481124.

[pmid15858839-6] Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, et al. (July 2005). "Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors". Synapse. 57 (1): 17–28. doi:10.1002/syn.20152. PMC 3726034. PMID 15858839.

[pmid17985117-7] Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, et al. (March 2008). "The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats". Psychopharmacology. 196 (4): 533–542. doi:10.1007/s00213-007-0986-6. PMC 3713235. PMID 17985117.

[pmid18306190-8] Hocke C, Prante O, Salama I, Hübner H, Löber S, Kuwert T, Gmeiner P (May 2008). "18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor". ChemMedChem. 3 (5): 788–793. doi:10.1002/cmdc.200700327. PMID 18306190. S2CID 23143152.

[9] Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, et al. (March 2010). "The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking". The International Journal of Neuropsychopharmacology. 13 (2): 181–190. doi:10.1017/S1461145709991064. PMID 19995481.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]